L-Asparaginase as the gold standard in the treatment of acute lymphoblastic leukemia : a comprehensive review
© 2023. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature..
L-Asparaginase is an antileukemic drug long approved for clinical use to treat childhood acute lymphoblastic leukemia, the most common cancer in this population worldwide. However, the efficacy and its use as a drug have been subject to debate due to the variety of adverse effects that patients treated with it present, as well as the prompt elimination in plasma, the need for multiple administrations, and high rates of allergic reactions. For this reason, the search for new, less immunogenic variants has long been the subject of study. This review presents the main aspects of the L-asparaginase enzyme from a structural, pharmacological, and clinical point of view, from the perspective of its use in chemotherapy protocols in conjunction with other drugs in the different treatment phases.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:40 |
|---|---|
| Enthalten in: |
Medical oncology (Northwood, London, England) - 40(2023), 5 vom: 15. Apr., Seite 150 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Tosta Pérez, María [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Acute lymphoblastic leukemia |
|---|
| Anmerkungen: |
Date Completed 18.04.2023 Date Revised 18.04.2023 published: Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1007/s12032-023-02014-9 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM355645939 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM355645939 | ||
| 003 | DE-627 | ||
| 005 | 20231226064801.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s12032-023-02014-9 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1185.xml |
| 035 | |a (DE-627)NLM355645939 | ||
| 035 | |a (NLM)37060469 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Tosta Pérez, María |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a L-Asparaginase as the gold standard in the treatment of acute lymphoblastic leukemia |b a comprehensive review |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 18.04.2023 | ||
| 500 | |a Date Revised 18.04.2023 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2023. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature. | ||
| 520 | |a L-Asparaginase is an antileukemic drug long approved for clinical use to treat childhood acute lymphoblastic leukemia, the most common cancer in this population worldwide. However, the efficacy and its use as a drug have been subject to debate due to the variety of adverse effects that patients treated with it present, as well as the prompt elimination in plasma, the need for multiple administrations, and high rates of allergic reactions. For this reason, the search for new, less immunogenic variants has long been the subject of study. This review presents the main aspects of the L-asparaginase enzyme from a structural, pharmacological, and clinical point of view, from the perspective of its use in chemotherapy protocols in conjunction with other drugs in the different treatment phases | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Acute lymphoblastic leukemia | |
| 650 | 4 | |a Antineoplastic agent | |
| 650 | 4 | |a Asparaginase | |
| 650 | 4 | |a Hypersensitivity | |
| 650 | 4 | |a Immunogenicity | |
| 650 | 7 | |a Asparaginase |2 NLM | |
| 650 | 7 | |a EC 3.5.1.1 |2 NLM | |
| 650 | 7 | |a Antineoplastic Agents |2 NLM | |
| 700 | 1 | |a Herrera Belén, Lisandra |e verfasserin |4 aut | |
| 700 | 1 | |a Letelier, Pablo |e verfasserin |4 aut | |
| 700 | 1 | |a Calle, Yolanda |e verfasserin |4 aut | |
| 700 | 1 | |a Pessoa, Adalberto |e verfasserin |4 aut | |
| 700 | 1 | |a Farías, Jorge G |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Medical oncology (Northwood, London, England) |d 1997 |g 40(2023), 5 vom: 15. Apr., Seite 150 |w (DE-627)NLM075077132 |x 1559-131X |7 nnns |
| 773 | 1 | 8 | |g volume:40 |g year:2023 |g number:5 |g day:15 |g month:04 |g pages:150 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s12032-023-02014-9 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 40 |j 2023 |e 5 |b 15 |c 04 |h 150 | ||